Evaluation of clinical outcome and economical aspects in the treatment of patients with peritoneal carcinomatosis.
Peritoneal carcinomatosis is a dooming finding with no hope for cure and a steadily decrease in quality of life. Cytoreductive surgery with intraperitoneal chemotherapy (CRS HIPEC) offers a small but proven chance for cure. The implementation of a CRS HIPEC and PIPAC programme in a Swiss tertiary care hospital is evaluated. When a patient is deemed non resectable, pressurized intraperitoneal aerosol chemotherapy (PIPAC) administered laparoscopically may confer effective palliation.
Study Type
OBSERVATIONAL
Enrollment
100
Kantonsspital Winterthur
Winterthur, Canton of Zurich, Switzerland
RECRUITINGPostoperative surgical complications
Reporting and grading of postoperative surgical complications (according to Dindo)
Time frame: 90 days
Rehospitalisation
Rehospitalisation: (yes/no), time frame, cause of rehospitalisation
Time frame: 90 days
Disease-free survival
Time to recurrence measured since diagnosis/Intervention (in months)
Time frame: 5 years
Overall Survival
All cause mortality since diagnosis/Intervention (in months)
Time frame: 5 years
Measurement of quality of life
Validated measurements of health-related quality of life according to the EORTC manual in terms of general quality of life: EORTC-QLQ30; disease-specific quality of life: EORTC-CR29 (colorectal cancers), and health-utility (EQ-5D).
Time frame: 5 years
Cost
At the level of individual patient Cost in terms of hospital charges and expenses in Swiss Francs
Time frame: 90 days
Revenues
At the level of individual patient Revenues in Swiss Francs as billed according to the DRG and case-mix index
Time frame: 90 days
Cost-utility analysis
Calculation and comparison of QUALY (quality-adjusted life years derived from EQ-5D) for competing treatment strategies taking advantage of published figures and own data, e.g. cost of a systemic palliative chemotherapy compared to cost of an intraperitoneal chemotherapy
Kantonsspital Winterthur
CONTACT
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: 90 days
Cost-effectiveness
Aggregation of costs, charges, and revenues for the whole series and comparison with alternative treatment option as clinically relevant, chemotherapy alone and palliative surgery alone.
Time frame: 90 days